Clinical trial companies prefer to screen multiple drugs in the early stages of development, so they can evaluate whether volunteer patients respond to the drugs in a way that makes it safe to progress to the next phase of research.
Volunteer patients on the other hand are largely unaware of the purpose of Phase 0 CRO clinical trials. The patient community, understandably, is more interested in the clinical implications of the new drug which is being tested, rather than whether it modulates the biological target or not.
Clinical Trial Companies and pharmas would like to know whether the new drug has the potential for fast and targeted development. However, they are also concerned about volunteer patients weighing up opportunity costs between Phase 0 CRO Clinical Trials which offer no therapeutic potential and a Phase 1 clinical trial which could offer a minimal benefit.
The common question Clinical Trial Companies face is whether Phase 0 trials are about the new drug …Read More